Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 9/20 | 0.44 |
| ▸ | CDK2 | P24941 | 9/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 3/20 | 0.38 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7666287 | 0.89 | PDGFRA (0.41) | CCNE1CDK2PDGFRANR3C1CTSL | |
| SCHEMBL7674135 | 0.87 | PDGFRA (0.43) | CCNE1CDK2PDGFRANR3C1CTSL | |
| SCHEMBL18232537 | 0.86 | PDGFRA (0.46) | CCNE1CDK2PDGFRANR3C1CTSL | |
| SCHEMBL20363222 | 0.84 | MEN1 (0.35) | POLBMEN1KMT2AKDM4ENFKB1 | |
| SCHEMBL7672313 | 0.84 | POLA1 (0.38) | CCNE1CDK2PDGFRANR3C1POLB | |
| SCHEMBL7670257 | 0.84 | PDGFRA (0.38) | CCNE1CDK2PDGFRANR3C1CTSL | |
| SCHEMBL7365457 | 0.84 | PDGFRA (0.39) | CCNE1CDK2PDGFRANR3C1CTSL | |
| SCHEMBL7661658 | 0.84 | PDGFRA (0.38) | CCNE1CDK2PDGFRANR3C1CTSL | |
| SCHEMBL7356565 | 0.84 | PDGFRA (0.38) | CCNE1CDK2PDGFRANR3C1CTSL | |
| SCHEMBL7661594 | 0.83 | CDK2 (0.43) | CCNE1CDK2PDGFRACTSLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180289718-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-10-11 | — | — | US | claimed |
| EP-3099672-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO Pharmaceutical Co., Ltd. (JP) | 2016-12-07 | — | — | EP | claimed |
| US-20160331757-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-11-17 | — | — | US | claimed |
| WO-2015115673-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-06 | — | — | WO | claimed |
| US-20180289718-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-10-11 | — | — | US | disclosed |
| US-10016439-B2 | Fused imidazole compounds | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-3099672-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO Pharmaceutical Co., Ltd. (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-20160331757-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160331757-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| WO-2015115673-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015115673-A1 | FUSED IMIDAZOLE COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-06 | — | — | WO | disclosed |
| US-6414147-B1 | DIAGNOSIS AND TREATMENT OF ANXIETY, DEPRESSION, SLEEP AND SEIZURE DISORDERS, DOWN'S SYNDROME, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR ENHANCEMENT OF MEMORY | NEUROGEN CORPORATION | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289718-A1 | FUSED IMIDAZOLE COMPOUNDS | GABRA5, CHRNA5, GABRP | CCNE1 3196/4885CDK2 3267/4885PDGFRA 2158/4885 |
| US-20160331757-A1 | FUSED IMIDAZOLE COMPOUNDS | GABRA5, CHRNA5, GABRP | CCNE1 3196/4885CDK2 3267/4885PDGFRA 2158/4885 |
| US-10016439-B2 | Fused imidazole compounds | GABRA5, CHRNA5, GABRP | CCNE1 3196/4885CDK2 3267/4885PDGFRA 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.